GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 7,900 Shares of Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 7,900 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00. Following the completion of the transaction, the chief financial officer owned 253,083 shares of the company’s stock, valued at $21,514,585.83. This represents a 3.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

GRAIL Trading Down 0.8%

GRAL stock opened at $79.37 on Tuesday. The company has a market cap of $3.55 billion, a P/E ratio of -8.14 and a beta of 3.24. GRAIL, Inc. has a 52 week low of $30.82 and a 52 week high of $118.84. The company’s 50-day moving average price is $71.28 and its 200 day moving average price is $63.22.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. On average, equities research analysts expect that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. HighTower Advisors LLC grew its holdings in GRAIL by 3.5% during the 2nd quarter. HighTower Advisors LLC now owns 40,565 shares of the company’s stock valued at $2,769,000 after buying an additional 1,357 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of GRAIL in the second quarter worth $1,171,000. California State Teachers Retirement System raised its holdings in shares of GRAIL by 6,569.8% in the second quarter. California State Teachers Retirement System now owns 2,966,058 shares of the company’s stock worth $202,493,000 after acquiring an additional 2,921,588 shares during the last quarter. HB Wealth Management LLC purchased a new stake in shares of GRAIL in the second quarter valued at $217,000. Finally, William John Sempolinski purchased a new stake in shares of GRAIL in the second quarter valued at $488,000.

Analyst Upgrades and Downgrades

GRAL has been the subject of several research reports. Wolfe Research initiated coverage on GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. TD Cowen reiterated a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Robert W. Baird set a $70.00 target price on GRAIL in a report on Wednesday, May 6th. Mizuho raised their price target on GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Finally, Piper Sandler lifted their price target on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GRAIL currently has a consensus rating of “Hold” and an average target price of $67.78.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.